Skip to main content
Advertising

Originally published November 12, 2014 at 1:06 PM | Page modified November 13, 2014 at 7:03 AM

  • Share:
             
  • Comments
  • Print

Dendreon urges ‘extreme caution’ in trading its shares

Dendreon said its shares will be delisted from Nasdaq next week and warned again that stockholders should expect to get nothing from its restructuring.


By Seattle Times business staff

advertising

Dendreon urged “extreme caution” for anyone thinking of buying the Seattle biotech company’s stock following its Monday bankruptcy filing, warning that the shares “will be highly speculative and will pose substantial risks.”

The company also said in a regulatory filing Wednesday that Nasdaq is expected to delist the stock effective Nov. 19, and Dendreon will not challenge that move.

Dendreon’s filing also reiterated that restructuring or liquidating its assets in Chapter 11 bankruptcy is likely to leave nothing for shareholders, and they will not get a vote on whatever reorganization plan emerges.

The warnings may seem obvious, but trading in Dendreon shares has been heavy since the bankruptcy filing before the market opened Monday. In regular trading Wednesday, the stock was up 6.6 percent or 1 cent to 16 cents.

Some of that trading may reflect short sellers who are closing out their positions rather than waiting for any further decline. Short sales — in which traders borrow shares and sell them, hoping to profit when the stock goes down — stood at 31.3 million shares or nearly 20 percent of outstanding shares on Oct. 31, according to Reuters.

But some commenters on Twitter seem to be promoting the idea that the stock would rise again, despite the warnings.

“Why do I get the feeling that $DNDN is gonna hit .40c lol??” wrote a Twitter user going by the name @mdela0880.

In Monday’s Chapter 11 filing, the company set a minimum bid of $275 million for its facilities and intellectual property; if no such bid emerges, ownership will be turned over to the noteholders who have $620 million in Dendreon convertible debt.

The company also said it expects production and availability of its prostate-cancer treatment Provenge to continue during the Chapter 11 process.



Four weeks for 99 cents of unlimited digital access to The Seattle Times. Try it now!

Also in Business & Technology

News where, when and how you want it

Email Icon

 Subscribe today!

Subscribe today!

99¢ for four weeks of unlimited digital access.

Advertising

Advertising

The Seattle Times photographs

Seattle space needle and mountains

Purchase The Seattle Times images


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►